Posted by ed_uk2010 on January 31, 2011, at 16:09:17
In reply to Re: Vilazodone Marketing, posted by bearfan on January 31, 2011, at 15:38:21
> Ed while you are correct, based on the Viibryd prescribing information, unlike the older SSRI trials, patients for Viibryd were asked to participate in the ASEX experience study and it was shown to be almost insignificant compared to placebo. Based on what I've read, the side effects (both short and long term) seem to be mild, my only question is what the efficacy is really in the real world. I remain cautiously optimistic. Although the nice thing is that this is a new compound, not like the last decade where there have been many reformulations or derivatives of the same compound.
I'm interested too.... are you wondering whether mild adverse effects might equal weak efficacy?
........at least at the recommended dose.
poster:ed_uk2010
thread:977653
URL: http://www.dr-bob.org/babble/20110130/msgs/978408.html